Nicotine Addiction, Smoking, Surgery
Conditions
Keywords
electronic cigarette, nicotine replacement therapy, smoking cessation, perioperative
Brief summary
The purpose of this pilot randomized trial is to determine the feasibility of e-cigarettes and telephone counselling (compared to transdermal nicotine replacement and telephone counselling) as a harm-reduction tool that may lead to increased smoking cessation in the perioperative setting in smokers presenting for elective surgery at the San Francisco Veterans Affairs Medical Center. Secondary outcomes include acceptability of e-cigarettes over transdermal nicotine replacement, length-of-stay in the post-anesthesia care unit, hospital length-of-stay, postoperative complications within the first 30-days, and smoking status 8-weeks after randomization. This pilot study is designed to provide the preliminary data necessary to plan and fund a larger-scale randomized clinical trial that will assess the utility of e-cigarettes in achieving smoking cessation perioperatively. Our ultimate goal is to add to the limited existing data on the safety and efficacy of e-cigarette use in smoking cessation, specifically in the perioperative setting where the risks of continued smoking are great and the motivation to stop is high.
Detailed description
It is well-known that smokers suffer more complications and higher risk of mortality after surgery than non-smokers. Despite this knowledge, it is unclear what clinicians can do to minimize this risk. Surgery represents a 'teachable moment' that might encourage smokers to engage in permanent cessation. Several small trials have shown that smoking cessation interventions can increase smoking cessation and reduce postoperative complications, particularly wound-healing complications, which can have an absolute risk reduction of up to 25%. Smoking cessation initiated in the perioperative period can also promote long-term smoking cessation. Despite the benefits of comprehensive smoking cessation interventions including nicotine replacement therapy, current standard of care at the SFVAMC does not routinely include specific preoperative smoking cessation pharmacotherapy or counselling. Although there is an urgent need for more data, e-cigarettes have been proposed as an alternative to nicotine replacement therapy that are at least as effective for smoking cessation, and may be more acceptable to some patients. The main hypothesis of this pilot study is that the use of e-cigarettes and telephone counselling, compared to telephone counselling and transdermal nicotine replacement, in the perioperative period results in increased smoking cessation on the day of surgery and at 8-weeks after randomization in smokers presenting for elective surgery. As secondary hypotheses, the study will also assess the acceptability of e-cigarettes versus nicotine patches, postoperative complications within the first 30-days, length-of-stay in the PACU and hospital length-of-stay. The investigators will examine the above hypotheses through the following aims: Aim 1) To determine how e-cigarettes plus counselling compare to transdermal nicotine replacement plus counselling for the achievement of smoking cessation, when introduced prior to elective surgery in veterans. The investigators plan to carry-out a pilot randomized controlled trial with parallel design comparing e-cigarettes and telephone counselling with transdermal nicotine replacement and telephone counselling. Our primary outcome is smoking cessation on the day of surgery, as confirmed biochemically by exhaled carbon monoxide. Smoking reduction (self-reported cigarettes per day) of 50% or more and bedside spirometry readings will be assessed as secondary outcomes. Aim 2) To determine the acceptability of e-cigarettes amongst veterans as an aid for smoking cessation and to determine the feasibility of recruitment, randomization, and follow-up procedures in preparation for large-scale trial. Through implementation of this pilot trial, the investigators will determine the feasibility and acceptability of e-cigarettes for smoking cessation perioperatively in the veteran population and obtain the preliminary data necessary to run a larger trial on the effectiveness of e-cigarettes as a perioperative smoking cessation aid. Aim 3) To determine the safety of e-cigarettes as a harm reduction strategy to achieve short-term perioperative smoking cessation. The investigators plan to improve the overall knowledge of the safety of short-term e-cigarettes use through careful surveillance for adverse events and side effects. Aim 4) To determine if e-cigarette use preoperatively is associated with a lower risk of complications postoperatively. The investigators plan to measure the following secondary outcomes: postoperative complications and mortality within the first 30 days, post-anesthesia care unit (PACU) length-of-stay, and hospital length-of-stay. This will help us understand if e-cigarettes have the potential to be used for harm-reduction perioperatively.
Interventions
As described above.
As described above.
Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible.
A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery. Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure\_%20For%20Posting.pdf
Sponsors
Study design
Eligibility
Inclusion criteria
* adults (age \>18) * any gender * scheduled to undergo elective surgery at the San Francisco Veterans Affairs Medical Center (SFVAMC) * daily smoker, based on self-report of at least 2 cigarettes/day and having smoked in the last 7 days * presenting to the anesthesia preoperative (APO) clinic at least 3 days preoperatively
Exclusion criteria
* emergency surgery (booked \<24 hours preoperatively) * consumers of non-cigarette forms of tobacco only (pipe, smokeless tobacco) or marijuana only * already enrolled in a smoking cessation trial * current smoking cessation pharmacotherapy * daily user of e-cigarettes * previous adverse reaction to e-cigarette or transdermal nicotine * poor proficiency of English language¸as indicated by need for an interpreter (including family members) at the preadmission visit * lacking capacity for consent (e.g. due to mental illness or dementia), as indicated by consent for surgery and other medical procedures being obtained from a substitute decision maker * pregnant or breastfeeding * unstable cardiac condition (unstable angina, unstable arrhythmia)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO) | day of surgery (expected average around 1-2 weeks after enrollment/randomization) | Confirmed abstinent. Abstinence confirmed with exhaled carbon monoxoide \<10ppm. Time Frame depends on date of preadmission clinic visit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Report of How Helpful the Product Was for Quitting | 8-weeks | 7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree |
| How Satisfied the Patient Was With the Product (E-cigarette or Patch) | 8-weeks | 7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree |
| How Likely the Patient Would be to Recommend the Product (E-cigarette or Patch) to Others | 8-weeks | 7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree |
| Smoking Status 8-weeks After Randomization (Confirmed by Exhaled CO) | 8-weeks | by self-report and confirmed by exhaled CO\<10ppm - confirmed abstinent |
| Smoking Reduction | on day of surgery and 8-weeks after randomization | 50% or less regular cigarette use compared to baseline as determined by asking participants to self-report daily cigarette use in cigarettes per day at each time point. |
| Number of Participants With Dual Use | on day of surgery and 8-weeks after randomization | use of both regular and e-cigarettes concurrently |
| Frequency of Use of Product - Number Reporting Use Daily or Most Days | 8-weeks | how often product (e-cigarette or patch) was used (everyday except while hospitalized, most days, a few times a week, once a week, less than once a week, not at all) Result reported is those that used the product daily or most days |
| Spirometry - FEV1 | day of surgery and 8-weeks | change in FEV1 (mL) compared to baseline |
| Cotinine Level (Change in) | day of surgery and 8-weeks | salivary |
| Number of Participants With Postoperative Complications (Composite) | 30-days postop | by chart review - research assistant or investigator examined notes and investigations postoperatively for complications by telephone self-report - patients were asked open-ended question about whether they experienced any postoperative complications |
| Long-term Smoking Status - Use of Conventional Cigarettes | 6 months | by self-report (7-day point prevalence) |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | 8 weeks | all patients will be asked about adverse events each time they are contacted (day of surgery, 30-days postoperatively, and 8-weeks after randomization), and they will also be able to call to report adverse events to the study team any time during the study. |
| Number of Participants Postoperative Complications (Composite) | 30-days postop | by telephone self-report |
| Spirometry - FEV1/FVC Change | day of surgery and 8-weeks | Change in FEV1/FVC from baseline to day of surgery / 8-weeks. FEV1/FVC is expressed in percent. For example, if FEV1/FVC was 75%, 80%, and 85% at baseline, day of surgery and 8-weeks, result is reported as change in FEV1/FVC being +5% and +10% for day of surgery and 8-weeks respectively. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Nicotine Replacement Therapy (NRT) As described above | 10 |
| Electronic Cigarette (END) As described above | 20 |
| Total | 30 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 1 | 1 |
Baseline characteristics
| Characteristic | Nicotine Replacement Therapy (NRT) | Electronic Cigarette (END) | Total |
|---|---|---|---|
| Age, Continuous | 53 years STANDARD_DEVIATION 10.6 | 54 years STANDARD_DEVIATION 12.7 | 54 years STANDARD_DEVIATION 12 |
| Cigarettes smoked per day | 10.8 cigarettes STANDARD_DEVIATION 6.6 | 15.3 cigarettes STANDARD_DEVIATION 10.5 | 13.8 cigarettes STANDARD_DEVIATION 9.2 |
| COPD | 1 Participants | 6 Participants | 7 Participants |
| Day seen prior to surgery | 16.5 days STANDARD_DEVIATION 9.5 | 11.2 days STANDARD_DEVIATION 7.9 | 13.0 days STANDARD_DEVIATION 8.4 |
| Diabetes | 0 Participants | 2 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 2 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 10 Participants | 18 Participants | 28 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Exhaled CO (ppm) | 16.1 ppm STANDARD_DEVIATION 7.7 | 21.7 ppm STANDARD_DEVIATION 11.5 | 19.8 ppm STANDARD_DEVIATION 10.2 |
| Fagerstrom score | 2.5 units on a scale out of 10 min 1 max 10 STANDARD_DEVIATION 0.9 | 3.7 units on a scale out of 10 min 1 max 10 STANDARD_DEVIATION 2.6 | 3.3 units on a scale out of 10 min 1 max 10 STANDARD_DEVIATION 2 |
| FEV1/FVC (%) | 105 percent STANDARD_DEVIATION 81.3 | 68.2 percent STANDARD_DEVIATION 13 | 80.5 percent STANDARD_DEVIATION 35.8 |
| FEV1 (L) | 3.14 L STANDARD_DEVIATION 1.35 | 2.78 L STANDARD_DEVIATION 1.11 | 2.9 L STANDARD_DEVIATION 1.2 |
| FVC (L) | 3.52 L STANDARD_DEVIATION 1.28 | 4.03 L STANDARD_DEVIATION 1.32 | 3.9 L STANDARD_DEVIATION 1.31 |
| Heart disease | 0 Participants | 1 Participants | 1 Participants |
| Hypertension | 3 Participants | 7 Participants | 10 Participants |
| Number of years smoking | 32 years STANDARD_DEVIATION 16.4 | 32 years STANDARD_DEVIATION 15.6 | 32 years STANDARD_DEVIATION 15.9 |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 5 Participants | 8 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 3 Participants | 3 Participants |
| Race (NIH/OMB) White | 5 Participants | 11 Participants | 16 Participants |
| Salivary cotinine (ng/ml) | 130.1 ng/ml STANDARD_DEVIATION 75.3 | 209.6 ng/ml STANDARD_DEVIATION 110.3 | 183.1 ng/ml STANDARD_DEVIATION 98.6 |
| Sex: Female, Male Female | 1 Participants | 2 Participants | 3 Participants |
| Sex: Female, Male Male | 9 Participants | 18 Participants | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 10 | 0 / 20 |
| other Total, other adverse events | 6 / 10 | 10 / 20 |
| serious Total, serious adverse events | 0 / 10 | 0 / 20 |
Outcome results
Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO)
Confirmed abstinent. Abstinence confirmed with exhaled carbon monoxoide \<10ppm. Time Frame depends on date of preadmission clinic visit
Time frame: day of surgery (expected average around 1-2 weeks after enrollment/randomization)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO) | 2 Participants |
| Electronic Cigarette (END) | Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO) | 3 Participants |
Cotinine Level (Change in)
salivary
Time frame: day of surgery and 8-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Nicotine Replacement Therapy (NRT) | Cotinine Level (Change in) | day of surgery | 106 ng/ml | Standard Deviation 137 |
| Nicotine Replacement Therapy (NRT) | Cotinine Level (Change in) | 8-weeks | 34 ng/ml | Standard Deviation 89 |
| Electronic Cigarette (END) | Cotinine Level (Change in) | day of surgery | 19 ng/ml | Standard Deviation 119 |
| Electronic Cigarette (END) | Cotinine Level (Change in) | 8-weeks | -48 ng/ml | Standard Deviation 103 |
Frequency of Use of Product - Number Reporting Use Daily or Most Days
how often product (e-cigarette or patch) was used (everyday except while hospitalized, most days, a few times a week, once a week, less than once a week, not at all) Result reported is those that used the product daily or most days
Time frame: 8-weeks
Population: in-person visit at 8-weeks, or make-up phone call if unavailable in-person
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | Frequency of Use of Product - Number Reporting Use Daily or Most Days | 6 Participants |
| Electronic Cigarette (END) | Frequency of Use of Product - Number Reporting Use Daily or Most Days | 16 Participants |
How Likely the Patient Would be to Recommend the Product (E-cigarette or Patch) to Others
7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree
Time frame: 8-weeks
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | How Likely the Patient Would be to Recommend the Product (E-cigarette or Patch) to Others | 7 units on a scale out of 7 |
| Electronic Cigarette (END) | How Likely the Patient Would be to Recommend the Product (E-cigarette or Patch) to Others | 6 units on a scale out of 7 |
How Satisfied the Patient Was With the Product (E-cigarette or Patch)
7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree
Time frame: 8-weeks
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | How Satisfied the Patient Was With the Product (E-cigarette or Patch) | 5 units on a scale out of 7 |
| Electronic Cigarette (END) | How Satisfied the Patient Was With the Product (E-cigarette or Patch) | 5.5 units on a scale out of 7 |
Long-term Smoking Status - Use of Conventional Cigarettes
by self-report (7-day point prevalence)
Time frame: 6 months
Population: those lost assumed to still be smoking
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | Long-term Smoking Status - Use of Conventional Cigarettes | 1 Participants |
| Electronic Cigarette (END) | Long-term Smoking Status - Use of Conventional Cigarettes | 5 Participants |
Number of Participants Postoperative Complications (Composite)
by telephone self-report
Time frame: 30-days postop
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | Number of Participants Postoperative Complications (Composite) | 2 Participants |
| Electronic Cigarette (END) | Number of Participants Postoperative Complications (Composite) | 5 Participants |
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
all patients will be asked about adverse events each time they are contacted (day of surgery, 30-days postoperatively, and 8-weeks after randomization), and they will also be able to call to report adverse events to the study team any time during the study.
Time frame: 8 weeks
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Nicotine Replacement Therapy (NRT) | Number of Participants With Adverse Events as a Measure of Safety and Tolerability | any adverse event | 3 Participants |
| Nicotine Replacement Therapy (NRT) | Number of Participants With Adverse Events as a Measure of Safety and Tolerability | moderate adverse event (required intervention) | 1 Participants |
| Electronic Cigarette (END) | Number of Participants With Adverse Events as a Measure of Safety and Tolerability | any adverse event | 10 Participants |
| Electronic Cigarette (END) | Number of Participants With Adverse Events as a Measure of Safety and Tolerability | moderate adverse event (required intervention) | 1 Participants |
Number of Participants With Dual Use
use of both regular and e-cigarettes concurrently
Time frame: on day of surgery and 8-weeks after randomization
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | Number of Participants With Dual Use | 3 Participants |
| Electronic Cigarette (END) | Number of Participants With Dual Use | 2 Participants |
Number of Participants With Postoperative Complications (Composite)
by chart review - research assistant or investigator examined notes and investigations postoperatively for complications by telephone self-report - patients were asked open-ended question about whether they experienced any postoperative complications
Time frame: 30-days postop
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Nicotine Replacement Therapy (NRT) | Number of Participants With Postoperative Complications (Composite) | by chart review | 6 Participants |
| Nicotine Replacement Therapy (NRT) | Number of Participants With Postoperative Complications (Composite) | by telephone self-report | 2 Participants |
| Electronic Cigarette (END) | Number of Participants With Postoperative Complications (Composite) | by chart review | 5 Participants |
| Electronic Cigarette (END) | Number of Participants With Postoperative Complications (Composite) | by telephone self-report | 5 Participants |
Report of How Helpful the Product Was for Quitting
7-point likert scale (strongly disagree to strongly agree) 1. strongly disagree 2. disagree 3. disagree somewhat 4. neither agree nor disagree 5. agree somewhat 6. agree 7. strongly agree
Time frame: 8-weeks
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | Report of How Helpful the Product Was for Quitting | 5 units on a scale out of 7 |
| Electronic Cigarette (END) | Report of How Helpful the Product Was for Quitting | 6 units on a scale out of 7 |
Smoking Reduction
50% or less regular cigarette use compared to baseline as determined by asking participants to self-report daily cigarette use in cigarettes per day at each time point.
Time frame: on day of surgery and 8-weeks after randomization
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | Smoking Reduction | 7 Participants |
| Electronic Cigarette (END) | Smoking Reduction | 13 Participants |
Smoking Status 8-weeks After Randomization (Confirmed by Exhaled CO)
by self-report and confirmed by exhaled CO\<10ppm - confirmed abstinent
Time frame: 8-weeks
Population: Those lost to follow-up assumed to still be smoking (1 in NRT group). Those who had telephone interview were unable to have exhaled CO verification (n=1 in NRT group, n=2 in END group). Since they were not verified by exhaled CO, they were not considered abstinent.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nicotine Replacement Therapy (NRT) | Smoking Status 8-weeks After Randomization (Confirmed by Exhaled CO) | 0 Participants |
| Electronic Cigarette (END) | Smoking Status 8-weeks After Randomization (Confirmed by Exhaled CO) | 3 Participants |
Spirometry - FEV1
change in FEV1 (mL) compared to baseline
Time frame: day of surgery and 8-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Nicotine Replacement Therapy (NRT) | Spirometry - FEV1 | change in FEV1 day of surgery | -236 mL | Standard Deviation 585 |
| Nicotine Replacement Therapy (NRT) | Spirometry - FEV1 | change in FEV1 8-weeks | -300 mL | Standard Deviation 497 |
| Electronic Cigarette (END) | Spirometry - FEV1 | change in FEV1 day of surgery | -163 mL | Standard Deviation 549 |
| Electronic Cigarette (END) | Spirometry - FEV1 | change in FEV1 8-weeks | 292 mL | Standard Deviation 503 |
Spirometry - FEV1/FVC Change
Change in FEV1/FVC from baseline to day of surgery / 8-weeks. FEV1/FVC is expressed in percent. For example, if FEV1/FVC was 75%, 80%, and 85% at baseline, day of surgery and 8-weeks, result is reported as change in FEV1/FVC being +5% and +10% for day of surgery and 8-weeks respectively.
Time frame: day of surgery and 8-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Nicotine Replacement Therapy (NRT) | Spirometry - FEV1/FVC Change | FEV1/FVC on day of surgery compared to baseline | -32.2 percent (change from baseline) | Standard Deviation 74 |
| Nicotine Replacement Therapy (NRT) | Spirometry - FEV1/FVC Change | FEV1/FVC at 8 weeks compared to baseline | -38.1 percent (change from baseline) | Standard Deviation 79.2 |
| Electronic Cigarette (END) | Spirometry - FEV1/FVC Change | FEV1/FVC on day of surgery compared to baseline | -1.6 percent (change from baseline) | Standard Deviation 8.2 |
| Electronic Cigarette (END) | Spirometry - FEV1/FVC Change | FEV1/FVC at 8 weeks compared to baseline | 2.0 percent (change from baseline) | Standard Deviation 10.5 |